{
    "nct_id": "NCT05783622",
    "official_title": "An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects with Advanced or Metastatic Solid Tumor Malignancies",
    "inclusion_criteria": "* Subjects ≥18 years of age at the time of signing informed consent\n* Histologically or cytologically documented locally advanced or metastatic NSCLC, SCCHN, CRC, RCC, SCLC, PDAC, TNBC\n* Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for the tumor type\n* Adequate organ function\n* At least 1 measurable lesion per RECIST 1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Treatment with anti-cancer therapy within 28 days or ≤5 elimination half-lives, whichever is earlier, before enrollment\n* Prior treatment with EGFR-targeted bispecific T cell engager or CAR-T cell therapy\n* Prior treatment with CD3 engaging bispecific antibodies\n* Clinically significant cardiovascular diseases\n* Active clinically significant infection (bacterial, viral, fungal, mycobacteria, or other)\n* On supplemental oxygen\n* Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment",
    "miscellaneous_criteria": ""
}